ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022
Persistent Disparities in Colorectal Cancer Screening: A Tell-Tale Sign for Implementing New Guidelines in Younger Adults.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Shaping the future of early-onset colorectal cancer prevention.Nature reviews. Cancer · 2026Review
- Rethinking Colorectal Cancer Screening: Culturally Tailored Navigation for Mailed FIT Kits in 45- to 49-Year-Olds.Journal of general internal medicine · 2026Article
- Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.Advances in therapy · 2026Article
- Rural-urban disparities in colorectal cancer screening in United States: Blinder-Oaxaca decomposition analysis of BRFSS data.Cancer causes & control : CCC · 2025Article
- Colorectal cancer screening in adults aged 45-49: provider availability, CT colonography access, and screening rates.Journal of the National Cancer Center · 2025Article
- Body mass index and colorectal cancer screening among cancer survivors: the role of sociodemographic characteristics.Cancer causes & control : CCC · 2025Article
- Persistent Poverty, Rural Location, and Racial Segregation Are Factors in Colorectal Cancer Screening in Low-Income and Uninsured Populations.Journal of the advanced practitioner in oncology · 2025Article
- Patient Perspectives on Personalized Risk Communication Using Polygenic Risk Scores to Inform Colorectal Cancer Screening Decisions.AJPM focus · 2025Article
- Trends in Colorectal Cancer Screening from the National Health Interview Survey: Analysis of the Impact of Different Modalities on Overall Screening Rates.Cancer prevention research (Philadelphia, Pa.) · 2024Article
- Correlates of U.S. Adults Aged 50-75 Years Having Had a Colorectal Cancer Screening Test.AJPM focus · 2024Article
- Screening Implications for Distribution of Colorectal Cancer Subsite by Age and Role of Flexible Sigmoidoscopy.Cancers · 2024Article
- Declines in Colorectal Cancer Incidence and Mortality Rates Slow Among Older Adults.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
- Article
- Black-White disparities in colorectal cancer outcomes: a simulation study of screening benefit.Journal of the National Cancer Institute. Monographs · 2023Article
- Racial Differences in Strength of Associations Between Colorectal Cancer Screening, Area Deprivation, Demographics, and Clinical Characteristics.Ochsner journal · 2023Article
- Intervention during wait time: identification and referral of individuals non-adherent for colorectal cancer screening.Emergency cancer care · 2022Article
- Adherence to Repeat Screening Completion for Colorectal Cancer Using the Multi-Target Stool DNA Test: Real-World Analysis of Patients from Federally Qualified Health Centers.Journal of primary care & community healthArticle
- Real-World Adherence to Multi-Target Stool DNA Testing for Colorectal Cancer Among Asian Americans.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIn May 2021, the U.S. Preventive Services Task Force began recommending initiating colorectal cancer screening at age 45 (vs. 50) years.
methodsWe estimated prevalence of colorectal cancer screening (by colonoscopy, sigmoidoscopy, CT colonography, or stool-based tests) in adults ages 50 to 75 years using data from the National Health Interview Survey in 2000, 2003, 2005, 2008, 2010, 2013, 2015, and 2018. For each survey year, we estimated prevalence by age, race/ethnicity, educational attainment, family income, and health insurance. We also compared increases in prevalence of screening from 2000 to 2018 in 5-year age groups (50-54, 55-59, 60-64, 65-69, and 70-75 years).
resultsOverall, prevalence of colorectal cancer screening increased from 36.7% in 2000 to 66.1% in 2018. Screening prevalence in 2018 was lowest for age 50 to 54 years (47.6%), Hispanics (56.5%), Asians (57.1%), and participants with less than a high school degree (53.6%), from low-income families (56.6%), or without insurance (39.7%). Increases in prevalence over time differed by five-year age group. For example, prevalence increased from 28.2% in 2000 to 47.6% in 2018 (+19.4%; 95% CI, 13.1-25.6) for age 50 to 54 years but from 46.4% to 78.0% (+31.6%; 95% CI, 25.4%-37.7%) for age 70 to 75 years. This pattern was consistent across race/ethnicity, educational attainment, family income, and health insurance.
conclusionsPrevalence of colorectal cancer screening remains low in adults ages 50 to 54 years. IMPACT: As new guidelines are implemented, care must be taken to ensure screening benefits are realized equally by all population groups, particularly newly eligible adults ages 45 to 49 years. See related commentary by Brawley, p. 1671.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.